Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares rose 10.3% during trading on Thursday . The stock traded as high as $7.85 and last traded at $7.71, with a volume of 363,886 shares traded. The stock had previously closed at $6.99.

A number of analysts have recently issued reports on KPTI shares. Zacks Investment Research raised shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 21st. Wedbush reissued an “outperform” rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, August 4th. Jefferies Group lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 target price for the company. in a research note on Wednesday, June 1st. Leerink Swann reissued a “buy” rating on shares of Karyopharm Therapeutics in a research note on Monday, June 27th. Finally, Raymond James Financial Inc. started coverage on shares of Karyopharm Therapeutics in a research note on Friday, May 27th. They set an “outperform” rating and a $13.00 target price for the company. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $17.25.

The stock’s market capitalization is $280.35 million. The company has a 50-day moving average price of $7.13 and a 200 day moving average price of $7.81.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, August 4th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.08. Analysts predict that Karyopharm Therapeutics Inc. will post ($3.27) EPS for the current fiscal year.

In other news, major shareholder Ltd Chione sold 18,824 shares of the stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $8.03, for a total transaction of $151,156.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

A hedge fund recently raised its stake in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC boosted its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned 0.25% of Karyopharm Therapeutics worth $1,167,000 at the end of the most recent quarter.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.